Dapagliflozin results in more patients with improved or resolved MASH without worsening of fibrosis, improved fibrosis without worsening of MASH.

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

A new study reveals that dapagliflozin, a common diabetes medication, could significantly improve conditions like metabolic ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the condition, which ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra), said accompanying editorial authors Leila Haddad, MD, and Sebastián ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...